Log In

 

Company Name : ResMed

Thursday, July 12, 2018 11:17AM IST (5:47AM GMT)

(BW)(CA-RESMED)

ResMed, Verily to Form Joint Venture to Help Reach Millions of Untreated Sleep Apnea Sufferers


South San Francisco, San Diego, United States

ResMed (NYSE: RMD, ASX: RMD), a global leader in sleep apnea treatment and connected health solutions, and Verily, an Alphabet company, announced their agreement to form a new joint venture.

 

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180711005254/en/

 

Combining ResMed’s expertise in sleep apnea and Verily’s advanced health data analytics technologies, the U.S.-based joint venture will study the health and financial impacts of undiagnosed and untreated sleep apnea, and develop software solutions that enable healthcare providers to more efficiently identify, diagnose, treat and manage individuals with sleep apnea and other breathing related sleep disorders.

 

Sleep apnea is a sleep breathing disorder that affects an estimated 54 million Americans (calculated based on a 16-country prevalence data study),1 and is associated with heart disease, stroke, type 2 diabetes and other life-threatening conditions. Despite the condition’s high prevalence and increasing public awareness, past research has shown that approximately 80 percent of individuals with obstructive sleep apnea are undiagnosed, 2 untreated and therefore unaware of their own risk and of the benefits that therapy could provide.

 

“The vast majority of people with sleep apnea don’t realize they have it, and therefore don’t seek accessible, effective treatment to mitigate its effects and long-term health risks,” said ResMed Chief Medical Officer Carlos M. Nunez, M.D. “The combined industry expertise, scalable infrastructure, and data analytics capabilities of ResMed and Verily can unlock meaningful ways to identify these individuals and support their journey to improved sleep, health and quality of life.”

 

“Approaching a widespread health problem like sleep apnea through collecting, organizing and activating health data is central to Verily’s mission,” said Jessica Mega, M.D., M.P.H., Chief Medical and Scientific Officer at Verily. "By better identifying at-risk individuals as well as generating real-world evidence regarding the value and effectiveness of treatment, this collaboration has the potential to improve outcomes for millions of people living with sleep apnea, and potentially other related conditions."

 

The joint venture, subject to customary closing conditions, including regulatory approvals, will operate as a separate venture from ResMed and Verily.

 

About ResMed

 

ResMed (NYSE: RMD, ASX: RMD), a world-leading connected health company with more than 5 million cloud-connected devices for daily remote patient monitoring, changes lives with every breath. Its award-winning devices and software solutions help treat and manage sleep apnea, chronic obstructive pulmonary disease and other respiratory conditions. Its 6,000-member team strives to improve patients’ quality of life, reduce the impact of chronic disease and save healthcare costs in more than 120 countries. ResMed.com

 

About Verily

 

Launched in 2015, Verily is a subsidiary of Alphabet focused on life sciences and healthcare. Verily’s mission is to make the world’s health data useful so that people enjoy healthier lives. Verily develops tools and devices to collect, organize and activate health data, and creates interventions to prevent and manage disease. Verily partners with leading life sciences, medical device and government organizations, using deep hardware, software, scientific, and healthcare expertise to enable faster development, meaningful advances, and deployment at scale. For more information, please visit www.verily.com

 
  1. Benjafield A et al. Am J Resp Crit Care Med 2018. Abstract presented at ATS 2018: https://www.atsjournals.org/doi/abs/10.1164/ajrccm-conference.2018.197.1_MeetingAbstracts.A3962#aff3 (full publication pending); Peppard PE et al. Am J Epidemiol 2013: https://www.ncbi.nlm.nih.gov/pubmed/23589584
  2. https://aasm.org/resources/pdf/sleep-apnea-economic-crisis.pdf

 

 

 
MULTIMEDIA AVAILABLE :
https://www.businesswire.com/news/home/20180711005254/en/


Click here for Media Contact Details
CONTACTS :

ResMed
For media:
Jayme Rubenstein, +1 858-836-6798
news@resmed.com
or
For investors:
Amy Wakeham, +1 858-836-5000
investorrelations@resmed.com
or
Verily
For media and investors:
Carolyn Wang, 415-736-2437
press@verily.com


More News from ResMed

18/09/2018 7:38PM

175 Million Europeans Have Sleep Apnoea, Highlighting Scale of Global Health Crisis

Roughly 175 million Europeans have obstructive sleep apnoea, according to a late-breaking abstract presented by ResMed today at the European Respiratory Society’s annual ERS Congress in Paris. Leading researchers ...

13/09/2018 6:00PM

ResMed Introduces Its First Minimal-contact Full Face CPAP Mask, AirFit F30

ResMed (NYSE: RMD) (ASX: RMD) today introduced its first minimal-contact full face CPAP mask, AirFit F30, the latest addition to its AirFit mask portfolio, which helps users reduce facial marks, wear glasses in bed and ...

01/09/2018 10:25AM

ResMed Files Patent Infringement Action against Fisher & Paykel

ResMed files new infringement action against Fisher & Paykel’s Simplus, Eson and Eson 2 masks in the International Trade Commission to stop their importation to and sale in the United States ResMed also ...

Similar News

23/09/2018 11:54AM

‘Spirit of Wipro’ Run 2018 Held in 125 Cities Across 34 Countries

Wipro Limited (NYSE: WIT, BSE: 507685, NSE: WIPRO), a leading global information technology, consulting and business process services company, today organized the 13th edition of the ‘Spirit of Wipro’ Run in 125 cities ...

No Image

22/09/2018 10:35AM

Florian Winterstein Becomes New CEO of Jedox

The supervisory board of Jedox AG, a leading vendor of business intelligence and enterprise planning software, has appointed Florian Winterstein as Chief Executive Officer (CEO) effective October 2, 2018. This ...